Yes. Wellpoint — the rebranded UniCare State Indemnity Plan, effective July 1, 2024 — covers Spravato (esketamine) for treatment-resistant depression for Massachusetts state and municipal employees and retirees enrolled through the Group Insurance Commission (GIC). Wellpoint is a GIC-exclusive carrier with approximately 200,000 members. This is structurally different from the Wellpoint Medicaid brand operating in other states (e.g., Iowa, Texas, Tennessee), which is an Anthem/Elevance Medicaid product with different policies. Spravato PA for Wellpoint MA is administered through CarelonRx (Wellpoint's medical-drug benefit manager) — not through CVS Caremark, which handles retail prescriptions for non-Medicare GIC members.
Across Lumin Health's 2026 commercial Spravato (esketamine) authorizations: 100% approval rate, with a median 4-day decision turnaround. Lumin Health's pre-submission medical-necessity review and standardized clinical documentation packet contribute to this outcome. Individual approval depends on plan-specific PA criteria — see Wellpoint's policy summary below.
Latest medical review on: May 5th, 2026. Medically reviewed by Instructor in Psychiatry at Harvard Medical School and Lumin Health Co-founder, Chief Medical Officer Dr. Ben Yudkoff.
Wellpoint covers Spravato for adults with treatment-resistant major depressive disorder when all of the following are documented (per CarelonRx Medical Drug Clinical Criteria CC-0086, published April 1, 2025, last reviewed February 21, 2025):
Exclusions per CC-0086: aneurysmal vascular disease (thoracic/abdominal aorta, intracranial, peripheral arterial vessels) or arteriovenous malformation; intracerebral hemorrhage; combined use with ketamine; severe hepatic impairment (Child-Pugh Class C); use as an anesthetic agent.
Initial authorization (TRD): 3 months. Maintenance reauthorization: 12 months, requiring at least a 50% reduction in depression symptoms compared to baseline using a standard rating scale.
Note: Lumin Health delivers Spravato (esketamine) — FDA-approved nasal spray — and intramuscular (IM) ketamine. Lumin Health does not deliver intravenous (IV) ketamine. Wellpoint's UM Clinical Guidelines explicitly note that “use of ketamine as an intravenous (IV) infusion is not FDA-approved and is not a covered benefit.” That exclusion applies to IV ketamine specifically and does not affect Spravato coverage at Lumin Health.
Wellpoint is one of several GIC-contracted carriers. The GIC also offers plans through Harvard Pilgrim Health Care, Mass General Brigham Health Plan, Health New England, and Tufts (Point32Health). Each carrier sets its own Spravato PA criteria. If you're a GIC member but not on a Wellpoint plan, see the relevant carrier's Spravato coverage page on Lumin Health's site, or call us for a consultation.
Two Massachusetts statutes are particularly relevant when a commercial insurer reviews a Spravato prior authorization:
The “deemed granted” rule. Under 211 CMR 52.07, a Massachusetts commercial carrier that fails to respond to a complete prior authorization request within two business days is deemed to have granted the authorization. This applies to all major Massachusetts commercial carriers — Aetna, Blue Cross Blue Shield of Massachusetts, Cigna, Harvard Pilgrim Health Care, Mass General Brigham Health Plan, UnitedHealthcare, and the Group Insurance Commission's contracted carriers.
External review through the Office of Patient Protection. If your commercial insurer denies a Spravato authorization, you have the right to request external review by the Health Policy Commission's Office of Patient Protection (OPP). The filing window is four months from the final internal denial; OPP issues decisions within 45 days. Historically, more than 40% of OPP external reviews resolve in the patient's favor — an unusually patient-favorable rate compared with most states' insurance-department-administered review processes.
The Massachusetts Group Insurance Commission (GIC) administers health, dental, vision, life, and other benefits for approximately 460,000 Massachusetts state employees, retirees, municipal employees, and their dependents. The GIC contracts with multiple commercial carriers (it is not itself an insurer). The GIC plan year runs July 1 – June 30, distinct from most commercial calendar-year plans.
GIC annual enrollment typically runs April 1 – May 1, with elections effective July 1. Mid-year carrier changes are limited to qualifying life events — meaning a state employee who needs Spravato cannot easily switch carriers mid-treatment to chase more favorable PA criteria. Wellpoint Member Services for GIC: 833-442-0411.
Lumin Health's Massachusetts locations (Newton, Cambridge, Woburn, Brookline) coordinate Wellpoint Spravato authorizations through CarelonRx, the Wellpoint medical-drug benefit manager:
Spravato treatment at Lumin Health is available at all four Massachusetts locations: Newton, Cambridge, Woburn, and Brookline. All Lumin Health Spravato locations are REMS-certified per FDA requirements.
How Wellpoint/GIC compares with other major Massachusetts commercial payers on published Spravato prior authorization criteria:
Each linked cell opens the full Lumin Health Spravato coverage page for that payer.
No. MA Wellpoint is the rebranded UniCare State Indemnity Plan, a GIC-exclusive carrier serving approximately 200,000 Massachusetts state and municipal employees, retirees, and their families. Other states' Wellpoint plans (Anthem/Elevance Medicaid brands) are unrelated products with different policies — for example, the Iowa Wellpoint PAM-021 Medicaid Spravato policy requires a psychiatrist or psychiatric/mental-health NP prescriber, while the CarelonRx CC-0086 commercial criteria governing MA GIC Wellpoint members do not name a prescriber-specialty requirement.
All major GIC-contracted carriers cover Spravato for treatment-resistant depression with prior authorization, but the criteria differ by carrier. The GIC offers plans through Wellpoint, Harvard Pilgrim, Mass General Brigham Health Plan, Health New England, and Tufts (Point32Health). This page covers the Wellpoint variant specifically. For other GIC carriers, see the corresponding payer's Spravato coverage page on Lumin Health's site, or contact us during a consultation.
Through CarelonRx at 833-293-0659 or via the CoverMyMeds provider portal — not through CVS Caremark. CVS Caremark administers the retail pharmacy benefit for non-Medicare GIC members, but Spravato is a medical-benefit specialty drug administered in-office, so its PA is routed through CarelonRx. The Wellpoint MA SOP (pr559-WLP, Rev 04/24) confirms this routing for S0013/J0013 (Spravato). HCPCS code J0013 became effective 1/1/2026 (replacing S0013).
Not for treatment-resistant depression as of the February 21, 2025 CarelonRx CC-0086 revision. Spravato monotherapy is permitted for TRD. (For the separate MDD-with-acute-suicidal-ideation indication, an oral antidepressant is required.)
Annual GIC open enrollment is typically April 1 – May 1, with elections effective July 1 (the GIC plan year). Mid-year changes require a qualifying life event — mental-health diagnosis or denial of Spravato is not, on its own, a qualifying event. State employees needing Spravato should plan ahead to the next open enrollment if their current GIC carrier's PA criteria are difficult to meet.
Step 1 — File a Level 1 internal appeal. Deadline: Per Massachusetts state mandate (M.G.L. c.176O), commercial members have 180 days from the date of service or claim denial to file an internal appeal with their carrier. Verify the exact deadline in your Wellpoint PLUS, Total Choice, or GIC Member Handbook (Appendix C/D) — Wellpoint MA's member-facing appeal deadline was not retrievable verbatim from the public site at the time this page was published. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: Compliance Coordinator, P.O. Box 27401, Mail Drop VA2002-N160, Richmond, VA 23279 (grievances). Phone: Member Services number on your ID card; 833-663-4176 (Wellpoint PLUS members). For Spravato-specific PA submission/appeal: CarelonRx 833-293-0659 or covermymeds.com.
Step 2 — Peer-to-peer (P2P) review. Wellpoint offers peer-to-peer review at the precertification stage through CarelonRx (medical-drug benefit administrator) for Spravato-specific cases. Your prescriber contacts CarelonRx at 833-293-0659 to request a P2P.
Step 3 — Expedited (urgent) appeal. Under Massachusetts state mandate (211 CMR 52), Wellpoint must resolve urgent internal appeals within 72 hours when delay jeopardizes the member's health. Expedited appeals can be filed before services are provided or while services are ongoing — they cannot be filed retrospectively after care has been completed.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Massachusetts external review is administered by the Health Policy Commission's Office of Patient Protection (OPP). Filing window: 4 months from the final internal denial. Decision timeline: 45 days. See Massachusetts state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. Wellpoint routes behavioral-health appeals through Carelon Behavioral Health (formerly Beacon Health Options) on the national Anthem/Wellpoint book. Wellpoint MA's specialty pharmacy benefit on the GIC commercial book is administered by CarelonRx — Spravato authorization sits at the medical/specialty-Rx interface, so the appeal lane depends on how your specific GIC plan benefits the drug. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the Wellpoint medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
Step 1 — File a Level 1 internal appeal. Deadline: Per Massachusetts state mandate (M.G.L. c.176O), commercial members have 180 days from the date of service or claim denial to file an internal appeal with their carrier. Verify the exact deadline in your Wellpoint PLUS, Total Choice, or GIC Member Handbook (Appendix C/D) — Wellpoint MA's member-facing appeal deadline was not retrievable verbatim from the public site at the time this page was published. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: Compliance Coordinator, P.O. Box 27401, Mail Drop VA2002-N160, Richmond, VA 23279 (grievances). Phone: Member Services number on your ID card; 833-663-4176 (Wellpoint PLUS members). For Spravato-specific PA submission/appeal: CarelonRx 833-293-0659 or covermymeds.com.
Step 2 — Peer-to-peer (P2P) review. Wellpoint offers peer-to-peer review at the precertification stage through CarelonRx (medical-drug benefit administrator) for Spravato-specific cases. Your prescriber contacts CarelonRx at 833-293-0659 to request a P2P.
Step 3 — Expedited (urgent) appeal. Under Massachusetts state mandate (211 CMR 52), Wellpoint must resolve urgent internal appeals within 72 hours when delay jeopardizes the member's health. Expedited appeals can be filed before services are provided or while services are ongoing — they cannot be filed retrospectively after care has been completed.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Massachusetts external review is administered by the Health Policy Commission's Office of Patient Protection (OPP). Filing window: 4 months from the final internal denial. Decision timeline: 45 days. See Massachusetts state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. Wellpoint routes behavioral-health appeals through Carelon Behavioral Health (formerly Beacon Health Options) on the national Anthem/Wellpoint book. Wellpoint MA's specialty pharmacy benefit on the GIC commercial book is administered by CarelonRx — Spravato authorization sits at the medical/specialty-Rx interface, so the appeal lane depends on how your specific GIC plan benefits the drug. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the Wellpoint medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
